Page 53 - 《中国药房》2023年5期
P. 53

System Xc-还可介导胱氨酸和谷氨酸在细胞内外的交换                      [10]  BAI Y Q,WANG W W,WANG L,et al. Obacunone at‐
          作用,其中胱氨酸在细胞内可先被还原为半胱氨酸,再                                tenuates liver fibrosis with enhancing anti-oxidant effects
                      [22]
          合成谷胱甘肽 。GPx4 又名磷脂过氧化氢谷胱甘肽过                              of  GPx4  and  inhibition  of  EMT[J].  Molecules,2021,26
          氧化物酶,是已知的唯一能够直接清除脂质过氧化物的                               (2):318.
          酶,可在谷胱甘肽的辅助作用下,将有害的脂质过氧化                           [11]  LI J,DENG S H,LI J,et al. Obacunone alleviates ferrop‐
                                                                  tosis during lipopolysaccharide-induced acute lung injury
          物还原为无害的物质,从而阻断脂质过氧化反应的发
                           [23]
          生,进而抑制铁死亡 。本研究结果显示,模型组小鼠                                by  upregulating  Nrf2-dependent  antioxidant  responses[J].
                                                                  Cell Mol Biol Lett,2022,27(1):29.
                      2+
          肾脏组织中Fe 浓度和血清中MDA含量均显著升高,血
                                                             [12]  LIU M N,LIU T L,SHANG P J,et al. Acetyl-11-keto-β-
          清中 T-SOD 活力显著降低,提示铁死亡的发生;经黄柏                            boswellic  acid  ameliorates  renal  interstitial  fibrosis  via
                                   2+
          酮干预后,小鼠肾脏组织中Fe 浓度和血清中MDA含量                              Klotho/TGF- β/Smad  signalling  pathway[J].  J  Cell  Mol
          均显著降低,血清中 T-SOD 活力显著升高,肾脏组织中                            Med,2018,22(10):4997-5007.
          Nrf2、GPx4、SLC7A11  mRNA( 黄 柏 酮 低 剂 量 组             [13]  WEBSTER A  C,NAGLER  E  V,MORTON  R  L,et  al.
          SLC7A11 mRNA 除外)和蛋白的表达水平均显著升高。                          Chronic  kidney  disease[J].  Lancet,2017,389(10075):
          这表明黄柏酮可通过激活Nrf2/GPx4信号通路来抑制铁                            1238-1252.
          死亡,从而改善UUO模型小鼠肾间质纤维化。                              [14] 《中成药治疗优势病种临床应用指南》标准化项目组. 中
              综上所述,黄柏酮可改善 UUO 模型小鼠的肾间质                            成药治疗慢性肾脏病 3~5 期(非透析)临床应用指南:
          纤维化,具体作用机制可能与激活Nrf2/GPx4信号通路、                           2020年[J]. 中国中西医结合杂志,2021,41(3):261-272.
                                                             [15]  程红新,杨晓萍,蒋雅红,等. 纤维连接蛋白在肾间质纤
          抑制铁死亡有关。
                                                                  维化大鼠肾组织中的表达[J]. 中国组织工程研究,2012,
          参考文献
                                                                  16(31):5837-5842.
          [ 1 ]  上海市肾内科临床质量控制中心专家组. 慢性肾脏病早
                                                             [16]  杨晓萍,张焕巧,赵瑾,等. 整合素连接激酶和α-平滑肌
              期筛查、诊断及防治指南:2022 年版[J]. 中华肾脏病杂                      肌动蛋白的表达与肾间质纤维化关系的研究[J]. 北京医
              志,2022,38(5):453-464.
                                                                  学,2007,29(10):600-603.
          [ 2 ]  BREYER  M  D,SUSZTAK  K.  The  next  generation  of
                                                             [17]  STOCKWELL B R,ANGELI J P F,BAYIR H,et al. Fer‐
              therapeutics for chronic kidney disease[J]. Nat Rev Drug
                                                                  roptosis:a regulated cell death nexus linking metabolism,
              Discov,2016,15(8):568-588.                          redox biology,and disease[J]. Cell,2017,171(2):273-285.
          [ 3 ]  DIXON S J,LEMBERG K M,LAMPRECHT M R,et al.
                                                             [18]  LI S W,ZHENG L S,ZHANG J,et al. Inhibition of fer‐
              Ferroptosis:an  iron-dependent  form  of  nonapoptotic  cell   roptosis by up-regulating Nrf2 delayed the progression of
              death[J]. Cell,2012,149(5):1060-1072.               diabetic nephropathy[J]. Free Radic Biol Med,2021,162:
          [ 4 ]  WANG J Y,LIU Y,WANG Y Q,et al. The cross-link be‐  435-449.
              tween ferroptosis and kidney diseases[J]. Oxid Med Cell   [19]  YANG L,GUO J,YU N,et al. Tocilizumab mimotope al‐
              Longev,2021,2021:6654887.                           leviates kidney injury and fibrosis by inhibiting IL-6 sig‐
          [ 5 ]  GAO  Y,HOU  R,LIU  F,et  al.  Obacunone  causes  sus‐  naling and ferroptosis in UUO model[J]. Life Sci,2020,
              tained expression of MKP-1 thus inactivating p38 MAPK   261:118487.
              to suppress pro-inflammatory mediators through intracel‐  [20]  KERINS M J,OOI A. The roles of Nrf2 in modulating cel‐
              lular MIF[J]. J Cell Biochem,2018,119(1):837-849.   lular iron homeostasis[J]. Antioxid Redox Signal,2018,29
          [ 6 ]  ZHOU J,WANG T Y,WANG H Z,et al. Obacunone at‐   (17):1756-1773.
              tenuates high glucose-induced oxidative damage in NRK-  [21]  ZHANG J,LIU L,LI F R,et al. Treatment with catalpol
              52E  cells  by  inhibiting  the  activity  of  GSK-3β[J].  Bio‐  protects  against  cisplatin-induced  renal  injury  through
              chem Biophys Res Commun,2019,513(1):226-233.        Nrf2  and  NF- κB  signaling  pathways[J].  Exp Ther  Med,
          [ 7 ]  MURTHY K N,JAYAPRAKASHA G K. Cytotoxicity of     2020,20(4):3025-3032.
              obacunone  and  obacunone  glucoside  in  human  prostate   [22]  SHIN C S,MISHRA P,WATROUS J D,et al. The gluta‐
              cancer cells involves Akt-mediated programmed cell death  mate/cystine  xCT  antiporter  antagonizes  glutamine  me‐
              [J]. Toxicology,2015,329:88-97.                     tabolism and reduces nutrient flexibility[J]. Nat Commun,
          [ 8 ]  QIU Z W,HE J Z,SHAO G Y,et al. Obacunone retards   2017,8:15074.
              renal cyst development in autosomal dominant polycystic   [23]  IMAI  H,MATSUOKA  M,KUMAGAI  T,et  al.  Lipid
              kidney  disease  by  activating  NRF2[J]. Antioxidants (Ba‐  peroxidation-dependent cell death regulated by GPx4 and
              sel),2021,11(1):38.                                 ferroptosis[J].  Curr  Top  Microbiol  Immunol,2017,403:
          [ 9 ]  XU S M,CHEN W M,XIE Q F,et al. Obacunone acti‐   143-170.
              vates the Nrf2-dependent antioxidant responses[J]. Protein    (收稿日期:2022-08-18  修回日期:2023-01-20)
              Cell,2016,7(9):684-688.                                                             (编辑:唐晓莲)


          中国药房  2023年第34卷第5期                                                 China Pharmacy  2023 Vol. 34  No. 5    · 559 ·
   48   49   50   51   52   53   54   55   56   57   58